tiprankstipranks
Trending News
More News >

Cybin initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Cybin (CYBN) with a Buy rating and $106 price target Cybin is developing alternative formulations and derivatives of psychedelic drugs, the analyst tells investors in a research note. The firm points out the Drug Enforcement Agency classifies both of Cybin’s drugs as Schedule I, meaning “drugs with no currently accepted medical use and high potential for abuse.”

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1